Gulf International Bank UK Ltd Sells 4,057 Shares of Illumina, Inc. $ILMN

Key Points

• Gulf International Bank UK Ltd reduced its position in Illumina, Inc. by 32.8%, selling 4,057 shares and bringing its total holdings to 8,311 shares valued at approximately $659,000.
• While Gulf International Bank is trimming its position, other investors like Capital World Investors and Vanguard Group have significantly increased their stakes, with Capital World Investors boosting its position by 408.6%.
• Analyst sentiment is mixed, with Evercore ISI raising Illumina's price target to $128 while Citigroup downgraded it to a strong sell with a target of $80.

Gulf International Bank UK Ltd cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 32.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,311 shares of the life sciences company's stock after selling 4,057 shares during the period. Gulf International Bank UK Ltd's holdings in Illumina were worth $659,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Rakuten Securities Inc. lifted its stake in shares of Illumina by 290.3% during the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after buying an additional 270 shares in the last quarter. Center for Financial Planning Inc. purchased a new position in shares of Illumina during the 1st quarter valued at $33,000. Fourth Dimension Wealth LLC purchased a new position in shares of Illumina during the 4th quarter valued at $40,000. PFS Partners LLC lifted its stake in shares of Illumina by 400.0% during the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after buying an additional 400 shares in the last quarter. Finally, Golden State Wealth Management LLC lifted its stake in shares of Illumina by 123.2% during the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after buying an additional 292 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

ILMN stock traded up $3.69 during mid-day trading on Friday, hitting $102.98. The company had a trading volume of 601,490 shares, compared to its average volume of 2,328,762. The company has a market capitalization of $15.83 billion, a price-to-earnings ratio of 13.00, a P/E/G ratio of 2.27 and a beta of 1.37. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average price of $97.88 and a 200 day moving average price of $89.28.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the firm posted $0.36 EPS. The business's quarterly revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of analyst reports. Morgan Stanley lifted their target price on shares of Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a research note on Monday, August 4th. Canaccord Genuity Group lifted their target price on shares of Illumina from $99.00 to $105.00 and gave the company a "hold" rating in a research note on Friday, August 1st. Guggenheim lowered their target price on shares of Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Wall Street Zen cut shares of Illumina from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Finally, Evercore ISI lifted their target price on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Seven investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $124.58.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.